Prescribing Information Visit Patient website

Not actual patients. LYNAVOY is not approved for use in children.

LYNAVOY delivers clinically meaningful itch
and sleep improvements1,6

Clinically meaningful itch relief over 24 weeks1,6

Primary Endpoint: Change from baseline in Monthly Itch Score* over 24 weeks1

Bar chart of LS mean change from baseline in Monthly Itch Score over 24 weeks: LYNAVOY (n=119; baseline 7.3) −2.9 versus placebo (n=118; baseline 7.4) −2.2, P=0.001. Clinically meaningful improvement is shaded from −2.5 to −4.0.

Clinically meaningful improvement in itch was defined by the FDA as a ≥2.5- to 4-point reduction from baseline over
24 weeks6

  • Statistically significant improvement from baseline vs placebo over 24 weeks
  • LS mean difference vs placebo:
    −0.7 (95% CI: −1.15 to −0.28); P=0.001

*The Monthly Itch Score was computed as the worst (highest) Weekly Itch Score within a 4-week period.1

CI=confidence interval; LS=least-squares.

Rapid itch relief: Nearly
2-point itch improvement at Week 21,7

Change from baseline in monthly itch score over 2 weeks

LYNAVOY improved itch by

66% more than
placebo at
Week 21†

Bar chart of LS mean change from baseline in monthly itch score over 2 weeks: LYNAVOY (n=119; baseline 7.3) −1.8 versus placebo (n=118; baseline 7.4) −1.1, P=0.0002.

†−0.7 LS mean difference, a 66% greater improvement for itch score compared to placebo.

LYNAVOY is the FIRST AND ONLY cholestatic pruritus in PBC treatment that achieved a statistically significant reduction in
itch at Week 21,2

Patients’ itch improved from severe to mild1,7

Mean monthly itch scores at baseline and Week 24 with LYNAVOY‡

Itch severity scale from 0 to 10, with severe, moderate, and mild bands, showing the mean monthly itch score with LYNAVOY improving from 7.3 at baseline to 3.8 at Week 24.

On average, patients on LYNAVOY improved their itch scores from severe (>7) at baseline to mild (<4) at 24 weeks1,7†

‡Monthly itch scores reduced from 7.3 at baseline to 4.5 at Week 24 with placebo.1,7

Not an actual patient.

Help keep itch from disrupting their sleep1

Clinically meaningful and significant improvement in pruritus-related sleep interference vs placebo over 24 weeks1,6

Key secondary endpoint: Change from baseline in monthly sleep1

-2.8 -point

mean change from baseline in pruritus-related sleep score at Week 24 with LYNAVOY

Bar chart of LS mean change from baseline in monthly sleep score over 24 weeks: LYNAVOY (n=119; baseline 6.3) −2.8 versus placebo (n=118; baseline 6.3) −2.2, P=0.024. Clinically meaningful improvement is shaded from −2.5 to −4.0.

Mean difference vs placebo: −0.53 (95% CI: −0.98 to −0.07); P=0.024

LYNAVOY is the only treatment proven to reduce pruritus-related sleep interference1

Changes in itch severity were observed following treatment switching in an exploratory analysis7

Patients who switched from LYNAVOY to placebo showed increased itch severity, while those who switched from placebo to LYNAVOY showed decreased itch severity7

Line chart of change from baseline in weekly itch score through Week 32. In Part A (all patients, Weeks 0–24) itch improved more with LYNAVOY than with placebo; in Part B (switch arms, Weeks 24–32) patients who crossed over to placebo worsened and patients who crossed over to LYNAVOY improved.

Patients previously treated with LYNAVOY who switched to placebo at Week 24 experienced an increase in mean itch severity within 2 weeks7

Part B was an 8-week, blinded, randomized, withdrawal period. Change in weekly itch score from Week 24 to Week 32 was an exploratory endpoint evaluating changes in pruritus following treatment continuation or withdrawal.7

Changes in itch severity observed during continuous LYNAVOY treatment8,9

Based on an interim analysis of data collected over 1 year from an ongoing, open-label study9

Eligible patients from a phase 3 GLISTEN and phase 2b GLIMMER trials could enroll in LLSAT, in which all patients received continuous oral LYNAVOY at 40 mg twice daily9

Change in WI-NRS weekly scores for patients receiving LYNAVOY in
GLISTEN Part A and who entered LLSAT8,9

Line chart of mean WI-NRS weekly score for patients receiving LYNAVOY in GLISTEN Part A, Part B, and the LLSAT open-label extension through week L52, highlighting a 4.9-point mean itch reduction after 52 continuous weeks of treatment with LYNAVOY.

§Based on a descriptive analysis of monthly WI-NRS scores in patients receiving 52 weeks of continuous linerixibat treatment (n=37). Mean change from baseline: −4.87 points. Weeks that start with “L” are the LLSAT weeks. Interim efficacy data (data cutoff: July 31, 2025). As this is an open-label, noncomparator study, no statistical test for comparison was performed. All analyses were descriptive with no inferential testing performed. LLSAT was a long-term study with frequency and severity of adverse events as the primary endpoint; maintenance of efficacy was assessed as a secondary endpoint.8,9

A study designed to measure itch relief for patients with cholestatic pruritus in PBC1,7

GLISTEN was a phase 3, randomized, double-blind, placebo-controlled study in cholestatic pruritus in PBC1,7,10

GLISTEN study design: after 6 to 8 weeks of screening, 238 patients with confirmed PBC and pruritus and a Monthly Itch Score of 4 or more were randomized 1:1:1:1 on Day 1 to LYNAVOY or placebo for Part A (24 weeks). In Part B (Weeks 24 to 32) patients continued or switched treatment, followed by 2 weeks of follow-up or rollover to a long-term, open-label study.

53% of patients had ALP <1.67.1

Patients were randomized to LYNAVOY or placebo in Part A, which evaluated the efficacy and safety of LYNAVOY over 24 weeks. In Part B, patients either continued treatment or transitioned to the alternate treatment group to evaluate changes in itch severity following continuation or withdrawal of treatment.1,7

Key efficacy endpoints:

  • Primary endpoint: Change from baseline in Monthly Itch Score over 24 weeks1
  • Secondary endpoints: Change from baseline in Weekly Itch Score at Week 2, and change from baseline in Monthly Sleep Score over 24 weeks1,7

Across the LYNAVOY and placebo groups, 97% of patients in GLISTEN were receiving UDCA, and 47% were receiving concomitant antipruritic drugs1,7

Itch assessment: Patients rated their worst itch severity each morning and evening using the 11-point WI-NRS (0=no itch; 10=worst imaginable itch).

  • Worst Daily Itch Score: Highest of the two scores (morning or evening) recorded in
    a day
  • Weekly Itch Score: Average of the Worst Daily Itch Scores over
    7 days
  • Monthly Itch Score: Worst (highest) Weekly Itch Score within a 4-week period

Sleep assessment: Patients rated pruritus-related sleep interference each morning
using the 11-point Sleep Interference NRS (0=no interference; 10=complete
interference).

  • Weekly Sleep Score: Average of the Daily Sleep Scores recorded over the 7 days in a
    week
  • Monthly Sleep Score: The worst (highest) Weekly Sleep Score within a 4-week period

ALP=alkaline phosphatase; CI=confidence interval; GLISTEN = Global Linerixibat Itch STudy of Efficacy and safety iN primary biliary cholangitis; LLSAT=Linerixibat Long-term Safety and Tolerability Study; LS=least-squares; NRS=Numeric Rating Scale; SE=standard error; UDCA=ursodeoxycholic acid; WI-NRS=Worst Itch Numeric Rating Scale.

Important Safety Information

Warnings and Precautions

Liver Test Elevations were observed more commonly in LYNAVOY-treated patients compared to placebo-treated patients.

  • Obtain baseline liver tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total bilirubin [TB], direct bilirubin [DB], alkaline phosphatase [ALP]) prior to initiating treatment with LYNAVOY and monitor the levels per standard clinical practice for PBC patients during treatment with LYNAVOY.
  • If new liver test elevations occur, monitor ALT, AST, TB, DB, and ALP more frequently.
  • If liver test elevations persist, discontinue LYNAVOY.

Diarrhea was reported as the most common adverse reaction in patients treated with LYNAVOY.

  • If diarrhea occurs, advise patients to monitor for dehydration.
  • Consider interrupting or discontinuing LYNAVOY treatment if diarrhea persists.

Fat-Soluble Vitamin (FSV) Deficiency: LYNAVOY may adversely affect absorption of FSV (i.e., vitamins A, D, E, and K).

  • Obtain serum levels for vitamins A, D, and E and INR prior to initiation of LYNAVOY.
  • Monitor the levels periodically during treatment, along with any clinical manifestations of FSV deficiency.
  • Supplement with FSV if a deficiency is diagnosed.
  • Consider discontinuing LYNAVOY if FSV deficiency persists or worsens despite adequate supplementation.
  • Bleeding was observed more frequently in LYNAVOY-treated patients compared to placebo-treated patients.
    • If bleeding occurs, interrupt LYNAVOY treatment and evaluate for potential FSV deficiency.
    • LYNAVOY can be restarted if FSV deficiency is corrected, levels are maintained, and bleeding has resolved.
  • Bone Fracture has been associated with IBAT inhibitors.
    • Monitor bone health and ensure adequate FSV levels.

Adverse Reactions

The most common adverse reactions (≥5%) are diarrhea, abdominal pain, nausea, increased ALT, hemorrhage, increased AST, headache, dyspepsia, gastroesophageal reflux disease, abdominal distension, dizziness, and arthralgia.

Drug Interactions

  • Effect of Bile Acid Binding Resins on LYNAVOY: Administer at least 4 hours before or 4 hours after administration of LYNAVOY.

To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals 1-844-782-4278 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please see the full Prescribing Information for LYNAVOY.

Indication:

LYNAVOY (linerixibat) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients.

Limitations of Use: Avoid use of LYNAVOY in patients with decompensated cirrhosis or those with prior or active hepatic decompensation events (e.g. variceal hemorrhage, ascites, hepatic encephalopathy).

References

  1. 1. LYNAVOY (linerixibat) Prescribing Information. Morristown, NJ: Intercept Pharmaceuticals.
  2. 2. Alfasigma. Linerixibat approved for use in the U.S. for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC). Press release. March 19, 2026. Accessed October 6, 2026. https://alfasigma.com/news-media/linerixibat-approved-for-use-in-the-u-s-for-the-treatment-of-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc
  3. 3. Kode V, Yimam KK. Cholestatic pruritus: pathophysiology, current management approach, and emerging therapies. Current Hepatology Reports. 2024;23(1):123-136. doi:10.1007/s11901-024-00638-7
  4. 4. Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389(10074):1114-1123. doi:10.1016/S0140-6736(17)30319-7
  5. 5. Naumann S, Haller D, Eisner P, Schweiggert-Weisz U. Mechanisms of interactions between bile acids and plant compounds-a review. Int J Mol Sci. 2020;21(18):6495. doi:10.3390/ijms21186495
  6. 6. Food and Drug Administration. LYNAVOY (linerixibat) NDA 220295: Integrated Review. Published 2026. Accessed August 4, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220295Orig1s000IntegratedR.pdf
  7. 7. Hirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22-33. doi:10.1016/S2468-1253(25)00192-X
  8. 8. Bowlus L. Long-term safety, tolerability and maintenance of efficacy of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: An interim analysis. Poster presented at: EASL 2026; May 27-30, 2026; Barcelona, Spain.
  9. 9. Bowlus CL, Gordon SC, Jones DE, et al. TOP-280: Long-term safety, tolerability and maintenance of efficacy of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis. J Hepatol. 2026;84(suppl 1):S295-S296. doi:10.1016/ S0168-8278(26/00974-8
  10. 10. Hirschfield GM. Supplement to: Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22-33. doi:10.1016/S2468-1253(25/00192-X